GURUFOCUS.COM » STOCK LIST » Healthcare » Healthcare Providers & Services » BioCorRx Inc (OTCPK:BICX) » Definitions » Capex-to-Operating-Cash-Flow

BioCorRx (BioCorRx) Capex-to-Operating-Cash-Flow : 0.00 (As of Dec. 2023)


View and export this data going back to 2009. Start your Free Trial

What is BioCorRx Capex-to-Operating-Cash-Flow?

Capex-to-Operating-Cash-Flow assesses how much of a company’s cash flow from operations is being devoted to capital expenditure. It’s also useful to distinguish whether the company is capital intensive or not.

BioCorRx's Capital Expenditure for the three months ended in Dec. 2023 was $0.00 Mil. Its Cash Flow from Operations for the three months ended in Dec. 2023 was $-0.53 Mil.

GuruFocus do not calculate Capex-to-Operating-Cash-Flow if the Cash Flow from Operations is negative.


BioCorRx Capex-to-Operating-Cash-Flow Historical Data

The historical data trend for BioCorRx's Capex-to-Operating-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

BioCorRx Capex-to-Operating-Cash-Flow Chart

BioCorRx Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Operating-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

BioCorRx Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Capex-to-Operating-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of BioCorRx's Capex-to-Operating-Cash-Flow

For the Medical Care Facilities subindustry, BioCorRx's Capex-to-Operating-Cash-Flow, along with its competitors' market caps and Capex-to-Operating-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


BioCorRx's Capex-to-Operating-Cash-Flow Distribution in the Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, BioCorRx's Capex-to-Operating-Cash-Flow distribution charts can be found below:

* The bar in red indicates where BioCorRx's Capex-to-Operating-Cash-Flow falls into.



BioCorRx Capex-to-Operating-Cash-Flow Calculation

BioCorRx's Capex-to-Operating-Cash-Flow for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -1.853
=N/A

BioCorRx's Capex-to-Operating-Cash-Flow for the quarter that ended in Dec. 2023 is calculated as

Capex-to-Operating-Cash-Flow=- Capital Expenditure / Cash Flow from Operations
=- (0) / -0.534
=N/A

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


BioCorRx  (OTCPK:BICX) Capex-to-Operating-Cash-Flow Explanation

Capex-to-Operating-Cash-Flow ratio assesses how much of a company’s Cash Flow from Operations is being devoted to Capital Expenditure. It is a good indicator in terms of how much the company is focused on growth. In general, a high Capex-to-Operating-Cash-Flow ratio indicates that the company is investing more in physical assets and is focused on growth and expansion. Conversely, lower ratio could indicate that a company has reached maturity and is no longer pursuing aggressive growth.

Moreover, the ratio is also useful to distinguish whether the company is capital intensive or not. If the ratio is large, then the company tends to be capital intensive. Lower ratio suggests that it’s a capital-light business. The ratio can be combined with ROIC % to identify whether the company is an asset-light business that has a high return on invested capital. This is one question investors commonly ask to see if a company qualifies as a good company.


BioCorRx Capex-to-Operating-Cash-Flow Related Terms

Thank you for viewing the detailed overview of BioCorRx's Capex-to-Operating-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


BioCorRx (BioCorRx) Business Description

Traded in Other Exchanges
N/A
Address
2390 East Orangewood Avenue, Suite 500, Anaheim, CA, USA, 92806
BioCorRx Inc through its subsidiaries, develops and provides treatment programs for substance abuse and related disorders. The BioCorRx Recovery Program is a non-addictive, medication-assisted treatment program for substance abuse that includes peer recovery support. The UnCraveRx Weight Loss Management Program is a medically assisted weight management program that is combined with a virtual platform application.
Executives
Louis C. Lucido director 2390 EAST ORANGEWOOD AVENUE, SUITE 500, ANAHEIM CA 92806
Joseph J Galligan director, 10 percent owner 333 SOUTH GRAND AVENUE, 18TH FLOOR, LOS ANGELES CA 90071
Harsha Murthy director 5209 38TH STREET,NW, WASHINGTON DC 20015
Luisa Ingargiola director 4826 BLUE JAY CIRCLE, PALM HARBOR FL 34683
Thomas Patrick Welch officer: Vice President of Operations 10453 SARAH ST., TOLUCA LAKE CA 91602
Kent Emry director, officer: Chief Executive Officer 2390 EAST ORANGEWOOD AVENUE, SUITE 500, ANAHEIM CA 92806
Brady James Granier director 13024 DELANO STREET, VALLEY GLEN CA 91401
Lourdes Felix director, officer: Chief Financial Officer 15 CALLE VERANO, RANCHO SANTA MARGARITA CA 92688
Jorge Jr Andrade director, officer: Chief Executive Officer PO BOX 5366, SANTA ANA CA 92704
Muller Neil Terrence Mr director, officer: President 13231 SANDHURST PLACE, SANTA ANA CA 92705

BioCorRx (BioCorRx) Headlines

From GuruFocus

BioCorRx to Present at the LD Micro Invitational XII on June 7th

By GuruFocusNews GuruFocusNews 06-10-2022

BioCorRx Business Update for the First Quarter of 2022

By GuruFocusNews GuruFocusNews 06-26-2022

BioCorRx to Present at the LD Micro Invitational XII on June 7th

By GuruFocusNews GuruFocusNews 07-10-2022